United Laboratories International Holdings Ltd - ESG Rating & Company Profile powered by AI
The report of United Laboratories International Holdings Ltd was prepared by All Street Sevva using proprietary artificial intelligence. The webpage contains a Q&A table about United Laboratories International Holdings Ltd. Alternative corporations in the scoring industry group for United Laboratories International Holdings Ltd are shown.
United Laboratories International Holdings Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 8.0, social score of 8.0 and governance score of 3.2.
6.4
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
389 | WuXi Biologics (Cayman) Inc | 6.6 | High |
401 | Oxford Cannabinoid Technologies Holdings PLC | 6.5 | High |
402 | United Laboratories International Holdings Ltd | 6.4 | High |
402 | Capricor Therapeutics Inc | 6.4 | High |
402 | Alembic Pharmaceuticals Ltd | 6.4 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does United Laboratories International Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?
Does United Laboratories International Holdings Ltd disclose current and historical energy intensity?
Does United Laboratories International Holdings Ltd report the average age of the workforce?
Does United Laboratories International Holdings Ltd reference operational or capital allocation in relation to climate change?
Does United Laboratories International Holdings Ltd disclose its ethnicity pay gap?
Does United Laboratories International Holdings Ltd disclose cybersecurity risks?
Does United Laboratories International Holdings Ltd offer flexible work?
Does United Laboratories International Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does United Laboratories International Holdings Ltd disclose the number of employees in R&D functions?
Does United Laboratories International Holdings Ltd conduct supply chain audits?
Does United Laboratories International Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does United Laboratories International Holdings Ltd conduct 360 degree staff reviews?
Does United Laboratories International Holdings Ltd disclose the individual responsible for D&I?
Does United Laboratories International Holdings Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does United Laboratories International Holdings Ltd disclose current and / or historical scope 2 emissions?
Does United Laboratories International Holdings Ltd disclose water use targets?
Does United Laboratories International Holdings Ltd have careers partnerships with academic institutions?
Did United Laboratories International Holdings Ltd have a product recall in the last two years?
Does United Laboratories International Holdings Ltd disclose incidents of discrimination?
Does United Laboratories International Holdings Ltd allow for Work Councils/Collective Agreements to be formed?
Has United Laboratories International Holdings Ltd issued a profit warning in the past 24 months?
Does United Laboratories International Holdings Ltd disclose parental leave metrics?
Does United Laboratories International Holdings Ltd disclose climate scenario or pathway analysis?
Does United Laboratories International Holdings Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does United Laboratories International Holdings Ltd disclose the pay ratio of women to men?
Does United Laboratories International Holdings Ltd support suppliers with sustainability related research and development?
Does United Laboratories International Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does United Laboratories International Holdings Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is United Laboratories International Holdings Ltd involved in embryonic stem cell research?
Does United Laboratories International Holdings Ltd disclose GHG and Air Emissions intensity?
Does United Laboratories International Holdings Ltd disclose its waste policy?
Does United Laboratories International Holdings Ltd report according to TCFD requirements?
Does United Laboratories International Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does United Laboratories International Holdings Ltd disclose energy use targets?
Does United Laboratories International Holdings Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does United Laboratories International Holdings Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for United Laboratories International Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.